![]() The burden of disease of stroke extends beyond the high mortality rate – up to 50% of all stroke survivors remain permanently disabled.įirst author Jason Palazzolo (pictured, left) investigated the SCE5-scuPA drug, which he thought could avoid several shortfalls of t-PA, the only FDA-approved clot-buster medication currently available to stroke patients. It is one of the top five leading causes of death for Australian men and women. Ischaemic stroke is caused when a blood vessel supplying blood to the brain is obstructed by a clot and accounts for 80 percent of all types of stroke. The findings were published in ‘Blood Advances’ late last month. The study, led by Professor Christoph Hagemeyer and Dr Be’eri Niego from the Australian Centre for Blood Diseases (ACBD), showed the potential of their new clot-busting agent ‘SCE5-scuPA’ in mouse stroke models. L-R: Prof Christoph Hagemeyer and Dr Be’eri Niego have published a study investigating a new drug for blood clots.Ī team of Monash University researchers has demonstrated that an innovative drug that removes blood clots improves the outcomes of acute ischaemic stroke and has a promising safety profile. Monash ‘Neuroscience in a Flash’ Competition 2020 LabArchives: Electronic Laboratory Notebooks MNHS Library: Written and Oral Communication Skills Support Summer and Winter semester unit offering information 2022-2023 (archive) Summer and Winter semester unit offering information 2021-2022 (archive) Summer and Winter semester unit offering information 2020-2021 (archive) Summer and Winter semester unit offering information 2019-2020 (archive) Summer and Winter semester unit offering information 2018-2019 (archive) Summer and Winter semester unit offering information Why study Medicine, Nursing and Health Sciences at Monash? ![]()
0 Comments
Leave a Reply. |